Skip to content
Aperlena
Language:

Belgium - Research and experimental development services - Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve

Upcoming Prior information notice No deadline published
Watch this tender

We email you if the deadline moves or a correction is published. Free. Log in

Summary

Machine-generated summary

The buyer is seeking to establish, pilot and maintain an EU-based reserve of investigational Filovirus candidate vaccines against Marburg (MARV) and/or Ebola Sudan (SUDV). The purpose is clinical trial preparedness for future outbreaks: reserve doses could be rapidly deployed, subject to conditions such as an actual outbreak and the Contracting Authority's consent, to advance vaccine development in phase 2 trials and beyond. The buyer and place are in Belgium. No estimated value, deadline, or detailed procedure information is stated in the notice, so interested tenderers should consult the full tender documents for those details.

Description

This call for tenders aims to ensure clinical trial preparedness for Filovirus outbreaks through the establishment of an EU-based reserve of investigational vaccines as a critical preparedness measure, given the sporadic yet high-consequence nature of these pathogens. Specifically, the call aims to establish, pilot and maintain an investigational reserve of Filovirus candidate vaccines against Marburg (MARV) and/or Ebola Sudan (SUDV), which - in case of an outbreak - could be used to advance their development by embedding them in outbreak-associated clinical trials, facilitated through international agreements and frameworks to support such preparedness. These provisions will allow for the rapid deployment of candidate vaccines for their later-stage development (phase 2 onwards). Tenderers will further have to ensure the rapid deployment of the investigational doses, subject to specific conditions being met (such as the occurrence of an outbreak and the expressed consent of the Contracting Authority).

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 1 month ago

View the official notice

More from this buyer

Full buyer profile

5 open tenders right now

Who usually wins this buyer's contracts in this sector

Company Wins Total awarded Last win
PREDICTBY RESEARCH AND CONSULTING S.L.; EUROPEAN BLOOD ALLIANCE; EEBA; ESHRE; EUROPEAN HEMATOLOGY ASSOCIATION; EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION; EHMSG; European Association of Tissue and Cell Banks, EATCB; EMBA 1 €3.5M Mar 2026
VERIAN GROUP BELGIUM 1 €900,250 Jan 2026
AGENCE DE LA BIOMEDECINE 1 n/a Feb 2026
NIVI Development P/S; ETHRIS; SSI; VISMEDERI SRL; ECRAID; BAVARIAN NORDIC; EVO; IDT; SANOFI R&D VACCINS; SVA 1 n/a Dec 2025

Based on 4 awards with a linked company profile over the last 5 years.

Change history

Every time an official source republished this notice with different content. We watch every source we index, including regional copies of the same notice.

  1. Read before bidding
    • Estimated value: Set to €16,000,000
    • Estimated value: Set to €16,000,000

Follow this tender and we email you the moment it changes. Create account

Similar tenders

Market context

Avg. open tender · Research & development
€3,272,461
534 open across Europe right now 389% above sector average
Buyer track record on Aperlena
30 notices tracked · 9 awarded
€17,719,420 in awarded contracts

Never miss a tender like this

5 new notices in Research & development in Belgium in the last 7 days. Get an email when new ones appear. Free.

Set up my alert
Source

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Jump to the search box
?
Show these shortcuts
Esc
Close